Cochrane Library

Draft template for assessment report for the development of European herbal monographs and European Union list entries - Revision 6

Retrieved on: 
목요일, 4월 18, 2024

The completed comments form should be sent to

Key Points: 
    • The completed comments form should be sent to
      [email protected]
      10
      11
      Keywords

      Committee on Herbal Medicinal Products; HMPC; European Union herbal
      monographs; European Union list of herbal substances, preparations and
      combinations thereof for use in traditional herbal medicinal products; herbal
      medicinal products; traditional herbal medicinal products; traditional use;
      well-established medicinal use; benefit-risk assessment; assessment report

      12

      1
      2

      Changes introduced in section 6 Overall conclusions.

    • Peer-reviewer

      If not the same peer-reviewer
      since last version, all peerreviewers should be listed, and
      the version specified in
      brackets.

    • 22

      23


      on
      .

    • It is a working

      24

      document, not yet edited, and shall be further developed after the release for consultation of the

      25


      .

    • The principle of the template is to make clear
      distinctions between presentation of data (methodology and results)
      and the assessment of the data (?assessor?s comment?).
    • likely from an article but it seems it is concluded by
      the rapporteur; ?According to the author? to be added.
    • Chapters with
      a heading including the word ?conclusion? should include a summary
      of all critical assessment of the assessor for that particular
      chapter.
    • If an assessor?s comment is not needed, the Rapporteur
      should delete the box inserted in the template.
    • ?
      The report should be sufficiently detailed to allow for secondary
      assessment of the available data by other HMPC experts.
    • Overview of available pharmacokinetic data regarding the herbal substance(s), herbal
      preparation(s) and relevant constituents thereof ........................................................... 16

      97
      98

      3.3.

    • Overall conclusions on clinical pharmacology and efficacy ........................................ 27

      Assessment report on
      EMA/HMPC/418902/2005

      Page 4/41

      119

      5.

    • This sections is related to
      available quality standards and there is no need to repeat information
      on all preparations included in the monograph.
    • Search and assessment methodology

      161

      The Rapporteur shall undertake a comprehensive search of relevant
      scientific literature and articles, Acts of law and regulations and
      other relevant sources.

    • Cross-reference to the list of
      references in Annex, which should list separately the references
      supporting the assessment report.
    • 143
      144
      145

      150
      151
      152
      153
      154

      162
      163
      164
      165
      166
      167
      168
      169
      170
      171
      172
      173
      174
      175

      Herbal substance(s)

      Herbal preparation(s)

      Relevant constituents for this assessment report

      Examples of scientific databases to be searched are Medline, PubMed,
      Cochrane Database of Systematic Reviews, EMBASE etc.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 6/41

      176
      177
      178
      179
      180
      181
      182
      183
      184
      185
      186
      187
      188
      189
      190
      191
      192

      Additional relevant references could also be retrieved from the checked
      references.

    • Examples of books are Hagers Handbuch, The Complete German
      Commission E Monographs, PDR for herbal medicines etc.
    • In addition, information from non-EU regulatory
      authorities for examples Health Canada monographs or WHO monographs
      could be searched, if relevant to herbal substances and preparations in
      EU.
    • 221

      225
      226
      227

      232

      When the assessment report is revised, the rapporteur should briefly
      summarise the main changes under this section.

    • Data are collected using the template entitled ?Document
      for information exchange for the preparation of the assessment report
      for the development of European Union monographs and for inclusion of
      herbal substance(s), preparation(s) or combinations thereof in the
      list? (EMEA/HMPC/137093/2006).
    • Assessment report on
      EMA/HMPC/418902/2005

      Page 8/41

      Herbal substance/

      Indication

      Posology and
      method of

      preparation

      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use
      As reported in
      the market
      overview

      As reported in
      the market
      overview

      As reported in
      the market
      overview.

    • Assessment report on
      EMA/HMPC/418902/2005

      Page 10/41

      Herbal substance/

      Indication/Medicinal

      Posology and

      preparation

      use

      method of
      administration

      Posology, age
      groups,
      pharmaceutical
      form, method of
      administration,
      duration of use

      Regulatory Status

      Type of
      regulatory
      status where
      possible, date,
      Country

      287

      This overview is not exhaustive.

    • Clinical Safety/Pharmacovigilance

      836
      837
      838
      839
      840
      841

      See ?Assessment of clinical safety and efficacy in the preparation of
      EU herbal monographs for well-established and traditional herbal
      medicinal products?(EMA/HMPC/104613/2005) for further details.

    • Overall conclusions on clinical safety

      1067

      1068

      In terms of structure, the conclusion should follow the presentation of
      the results above.

    • Overall conclusions

      1092

      1093

      1101

      Describe key aspects only briefly, these will already have been
      described in detail in the respective sections.

    • This section should
      cover all recommended ?well-established use? and ?traditional use?
      indications and conclusions shall be provided for each therapeutic
      indication and each herbal preparation.
    • 1102

      Well established use monograph

      1103
      1104

      The clinical studies supporting well-established use should be
      specified for each therapeutic indication and each herbal preparation.

    • The choice for the wording of traditional use indications vis-?vis existing wordings in monographs in the same therapeutic area should
      be briefly discussed/justified.
    • 1153

      List entry

      1154

      The conclusions should include a statement pointing to the
      possibility/non-possibility to support a European Union list entry.

FDA Clearance Granted for First AI-Powered Medical Device to Detect All Three Common Skin Cancers (Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma)

Retrieved on: 
수요일, 1월 17, 2024

Better identifying skin cancer in a primary care setting is designed to accelerate patient access to necessary care.

Key Points: 
  • Better identifying skin cancer in a primary care setting is designed to accelerate patient access to necessary care.
  • The good news is that 99 percent of skin cancers, including the most deadly form, melanoma, are curable if detected early.
  • The company has conducted 13 clinical studies in the last decade, six of which provided the principal support for FDA clearance.
  • Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physician’s Detection of Skin Cancers.

WellnessEvidence.com Adds CBD to Its Growing List of Wellness Approaches with Aim of Empowering Consumers to Make More Informed Decisions

Retrieved on: 
화요일, 6월 27, 2023

MIAMI, June 27, 2023 /PRNewswire-PRWeb/ -- The nonprofit Global Wellness Institute™ (GWI), the leading research and educational resource for the global wellness industry, reminds wellness seekers that there is evidence-based medical research available on most mainstream wellness modalities – whether that evidence is good, bad or inconclusive.

Key Points: 
  • "CBD, a non-psychoactive part of the cannabis sativa plant, has recently soared in popularity and has seen a lot of marketing hype as a cure-all.
  • While studies are increasing, unlike the overwhelmingly positive evidence for approaches such as exercise or healthy sleep, the evidence around CBD can be complex and confusing," continued Ellis.
  • WellnessEvidence.com is a 'spin-free' research zone where you can research studies for CBD, whether positive or negative.
  • To access the medical evidence for the 33 featured wellness approaches, visit http://www.wellnessevidence.com .

Cochrane Oral Health Collaborating Center Launched at Penn Dental Medicine

Retrieved on: 
금요일, 5월 12, 2023

PHILADELPHIA, May 12, 2023 /PRNewswire/ -- Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH) has partnered with Cochrane Oral Health to form the Cochrane Oral Health Collaborating Center at Penn Dental Medicine .

Key Points: 
  • PHILADELPHIA, May 12, 2023 /PRNewswire/ -- Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH) has partnered with Cochrane Oral Health to form the Cochrane Oral Health Collaborating Center at Penn Dental Medicine .
  • The Cochrane Oral Health Collaborating Center at Penn Dental Medicine will build upon the work of Cochrane Oral Health, engaging researchers from around the globe in systematic reviews summarizing the best available evidence on oral health topics to help clinicians, policymakers, patients, and caregivers make well-informed decisions.
  • Cochrane Oral Health publishes its reviews, updates, and protocols in the Cochrane Library and those produced through the Collaborating Center at Penn Dental Medicine will become part of the Cochrane Library as well.
  • "This partnership places Penn Dental Medicine at the center of the oral-health-evidence-synthesis field globally and aligns with the School's mission to transform global oral health and well-being through exceptional clinical care, innovation, education, and research," says Dr. Alonso Carrasco-Labra , Director of the Cochrane Oral Health Collaborating Center at Penn Dental Medicine.

New Cochrane Review Recognizes the Powerful Impact of Cranberry for UTI Prevention

Retrieved on: 
목요일, 4월 27, 2023

CARVER, Mass., April 27, 2023 /PRNewswire/ -- In the most comprehensive review to date, new findings published in The Cochrane Database of Systematic Reviews have positive news for those who suffer from urinary tract infections (UTIs). Cranberry juice, and cranberry supplements, have been shown to prevent and reduce the risk of repeat UTIs in women, children, and other at-risk individuals.

Key Points: 
  • Cranberry juice, and cranberry supplements, have been shown to prevent and reduce the risk of repeat UTIs in women, children, and other at-risk individuals.
  • The science has long shown that cranberry products can prevent UTIs, and now this review further bolsters evidence to prove their efficacy.
  • Study authors conducted a large-scale meta-analysis of 50 clinical trials, in which the objective was to assess the effectiveness of cranberry products in preventing UTIs in susceptible populations.
  • We have determined that PACs in juice-based products are most effective for UTI prevention and should be consumed daily2," says Howell.

Detecting COVID-19 using only a smartphone

Retrieved on: 
화요일, 3월 22, 2022

BRISBANE, Australia, March 21, 2022 /PRNewswire/ -- ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone.

Key Points: 
  • BRISBANE, Australia, March 21, 2022 /PRNewswire/ -- ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone.
  • ResApp will position this as a non-invasive, instant, smartphone only screening test to rule out COVID-19 and be used prior to a rapid antigen (RAT) or PCR test.
  • In the trial, the test achieved a sensitivity of 92% (better than real-world data on rapid antigen tests[i],[ii]) and a specificity of 80%.
  • The performance of the algorithm was obtained using K-fold cross-validation to provide an estimate of performance on unseen data.

Detecting COVID-19 using only a smartphone

Retrieved on: 
화요일, 3월 22, 2022

BRISBANE, Australia, March 21, 2022 /PRNewswire/ -- ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone.

Key Points: 
  • BRISBANE, Australia, March 21, 2022 /PRNewswire/ -- ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-19 screening test that only requires a smartphone.
  • ResApp will position this as a non-invasive, instant, smartphone only screening test to rule out COVID-19 and be used prior to a rapid antigen (RAT) or PCR test.
  • In the trial, the test achieved a sensitivity of 92% (better than real-world data on rapid antigen tests[i],[ii]) and a specificity of 80%.
  • The performance of the algorithm was obtained using K-fold cross-validation to provide an estimate of performance on unseen data.